Wire · opportunities
BillionToOne Debuts Northstar Origin Liquid Biopsy for Cancer Tissue Identification
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 September 2026 · Fusion42 review
BillionToOne launched Northstar Origin, a liquid biopsy add-on test that predicts cancer tissue of origin from cell-free DNA to help diagnose cancers of unknown primary, alongside expanding its genomic profiling panel to 102 genes for advanced solid tumors. The test aims to improve diagnostic accuracy and reduce additional biopsies, enhancing access to personalised cancer therapy.
This Wire brief tracks EternaFusion, and It sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You can now offer a single blood test that helps accurately identify cancer origin where traditional methods fail, opening a new route to personalised treatment and reducing costly biopsies.
◆ Mentioned in this story
◆ Coverage
1 source · 1 Sep 2026
◆ Related on Wire
◆ Topics